Department of General Surgery, Stanford University School of Medicine, Stanford, California.
Division of Thoracic Surgery, Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, California.
Ann Thorac Surg. 2020 Apr;109(4):1294-1301. doi: 10.1016/j.athoracsur.2019.08.104. Epub 2019 Oct 5.
Talcum has been used in pleurodesis for more than 8 decades. Despite a wealth of research, controversy remains over the optimal sclerosant for pneumothorax and pleural effusions. Talc's historical primacy has been challenged because of its potential for pulmonary toxicity, possible carcinogenicity, and recent concerns surrounding availability and legal liability, thus making this an ideal time for a review.
This systematic review of the talc literature, focused on publications after the year 2000, evaluated mechanism of action, efficacy, side effect profile, and alternative sclerosants; included is an overview of current socioeconomic and legal controversies.
The data support talc as the most effective agent for pleurodesis. There is evidence to suggest that mean particle size has a direct relationship with the side effect profile and that significant hypoxemic events after talc administration are exceedingly rare when using available graded talc preparations. Concerns regarding the development of malignant diseases after topical talc application remain incompletely resolved but appear related to cosmetic powder preparations that were contaminated with asbestos. Purified talc in the pleural space has not been implicated. Recent difficulties accessing commercial talc preparations have been solved. Although safe and effective talc alternatives do exist, these agents are not as well studied.
Talc pleurodesis with modern, purified, graded talc preparations is safe and highly effective. Talc is an inexpensive and accessible option that remains appropriate for pleurodesis despite existing controversies.
滑石粉在胸膜固定术的应用已有 80 多年的历史。尽管有大量的研究,但在气胸和胸腔积液的最佳硬化剂方面仍存在争议。由于滑石粉具有潜在的肺毒性、可能的致癌性以及最近对其供应和法律责任的担忧,滑石粉的历史主导地位受到了挑战,因此,现在是对其进行审查的理想时机。
本系统回顾了滑石粉文献,重点关注 2000 年后的出版物,评估了其作用机制、疗效、副作用概况和替代硬化剂;并概述了当前的社会经济和法律争议。
数据支持滑石粉作为胸膜固定术最有效的药物。有证据表明,平均粒径与副作用概况直接相关,并且在使用现有的分级滑石粉制剂时,滑石粉给药后发生严重低氧血症的情况极为罕见。关于局部滑石粉应用后恶性疾病发展的担忧仍未完全解决,但似乎与被石棉污染的美容粉制剂有关。胸膜腔内的纯化滑石粉并未被牵连。最近在获得商业滑石粉制剂方面的困难已经得到解决。虽然确实存在安全有效的滑石粉替代品,但这些制剂的研究还不够充分。
使用现代、纯化、分级的滑石粉制剂进行滑石粉胸膜固定术是安全且非常有效的。尽管存在争议,但滑石粉仍然是一种廉价且易于获得的选择,适用于胸膜固定术。